Long acting GLP-1 receptor agonist (injectable)
Taspoglutide 20 mg subcutaneous once weekly
TASP_SC_20MG_QW
Development discontinued.
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.11 (-1.45 to -0.78) | 0.73 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.28 (-0.19 to 0.79) | 0.33 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.18 (-3.65 to 1.94) | 0.51 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.74 (-3.05 to -0.48) | 0.72 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.21 (0.00 to 6.40) | 0.59 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.16 (0.60 to 2.17) | 0.58 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.48 (-5.32 to 0.32) | 0.55 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.93 (-1.61 to 9.58) | 0.40 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.81 (0.51 to 1.25) | 0.60 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.73 (1.87 to 7.52) | 0.24 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.03 (4.23 to 8.60) | 0.18 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.72 (5.08 to 12.07) | 0.17 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.64 (1.13 to 2.41) | 0.49 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.99 (2.08 to 8.07) | 0.17 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.70 (0.55 to 13.54) | 0.40 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.54 (0.04 to 6.36) | 0.57 |
Trials
- NCT00754988A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.2008 · 666 randomized · 156 weeks
- NCT00717457Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus2008 · 1,189 randomized · 52 weeks
- NCT00744926A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise2008 · 373 randomized · 24 weeks
- NCT00460941A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.2007 · 133 randomized · 8 weeks
- NCT00423501A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.2007 · 306 randomized · 8 weeks